Illumina's Early Deal Close Draws EU 'Interim Measures'
European Union antitrust officials moved Monday to punish Illumina with undisclosed "interim measures" over the DNA sequencing company's "unprecedented" decision to close its $8 billion reacquisition of cancer-testing outfit Grail while...To view the full article, register now.
Already a subscriber? Click here to view full article